{"id":41139,"date":"2025-10-27T12:30:00","date_gmt":"2025-10-27T12:30:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4807271_CN07271_0"},"modified":"2025-10-27T12:30:00","modified_gmt":"2025-10-27T12:30:00","slug":"biodlink-completes-first-international-shipment-of-bevacizumab-to-colombia","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=41139","title":{"rendered":"BioDlink Completes First International Shipment of Bevacizumab to Colombia"},"content":{"rendered":"<div id=\"dvContent\" readability=\"160.23931765485\">\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><span>Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in <span class=\"xn-location\">Colombia<\/span><\/span><sup>[1]<\/sup><span>.<\/span><\/li>\n<li><span>This <\/span><span>inaugural<\/span><span> shipment\u2014<\/span><span>dispatched around two months after <span class=\"xn-location\">Colombia&#8217;s<\/span> marketing approval<\/span><span>\u2014<\/span><span>demonstrates the company&#8217;s efficiency, while validating its <\/span><span>antibody commercialization platform, as well as robust production quality and supply chain management systems.<\/span><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">SUZHOU, <span class=\"xn-location\">China<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <b><u><a href=\"http:\/\/www.biodlink.com\/\" target=\"_blank\" rel=\"nofollow noopener\">BioDlink<\/a><\/u><\/b> announced the first international shipment of its bevacizumab injection biosimilar to <span class=\"xn-location\">Colombia<\/span> in partnership with Kexing BioPharm. Both companies marked this milestone with a special ceremony when specially-decorated transport vehicles arrived.<\/p>\n<p>Bevacizumab, a monoclonal antibody targeting <a href=\"https:\/\/www.news-medical.net\/life-sciences\/What-is-VEGF.aspx\" target=\"_blank\" rel=\"nofollow noopener\">vascular endothelial growth factor<\/a>&nbsp;(VEGF), is widely used in the treatment of various cancers, including metastatic colorectal cancer (mCRC) and metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC). According to industry estimates, bevacizumab injection achieved global sales of <span class=\"xn-money\">USD 8.5 billion<\/span> in 2023<sup>[2]<\/sup>.<\/p>\n<p>In <span class=\"xn-chron\">July 2025<\/span>, the company announced that its bevacizumab injection has received marketing approval from <span class=\"xn-location\">Colombia&#8217;s<\/span> National Institute for Surveillance of Medicines and Foods (INVIMA). This inaugural shipment\u2014dispatched around two months after marketing approval\u2014demonstrates BioDlink&#8217;s&nbsp;efficiency, while validating&nbsp;its antibody commercialization platform, as well as robust production quality and supply chain management systems. BioDlink&#8217;s 50,000-square-meter manufacturing facilities have successfully undergone EU Qualified Person (QP) audits for antibody drugs and ADCs five times in the past four years, with zero critical defects noted. BioDlink&#8217;s global-quality system is robust, delivering over 100 clinical projects with development, clinical filings, and manufacturing services worldwide, including <span class=\"xn-location\">Europe<\/span> and the U.S.<\/p>\n<p>Following GMP certification in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Colombia<\/span>, <span class=\"xn-location\">Brazil<\/span>, <span class=\"xn-location\">Argentina<\/span>, <span class=\"xn-location\">Egypt<\/span>, <span class=\"xn-location\">Indonesia<\/span>, <span class=\"xn-location\">Pakistan<\/span> and <span class=\"xn-location\">Thailand<\/span>, Kexing BioPharm, the global licensee for bevacizumab injection in emerging markets, has initiated regulatory filings in 35 countries in close collaboration with BioDlink. GMP certification in <span class=\"xn-location\">Brazil<\/span>, <span class=\"xn-location\">Colombia<\/span> and <span class=\"xn-location\">Argentina<\/span> covers the top three most populous countries in <span class=\"xn-location\">South America<\/span>, representing 71.4 % of the continent&#8217;s population<sup>[3]<\/sup>.<\/p>\n<p><span class=\"xn-location\">Colombia&#8217;s<\/span> ongoing cancer burden patterns (117,620 new cases in 2022, with 11,163 colorectal and 7,196 lung cases<sup>[1]<\/sup>) aligns closely with bevacizumab&#8217;s treatment areas of metastatic colorectal and non-squamous non-small cell NSCLC among others, making this initial international shipment both strategically important and timely.<\/p>\n<p>Since BioDlink signed an international commercialization agreement with Kexing BioPharm in early 2022, both two companies have achieved a complementary and efficient closed-loop &#8220;R&amp;D-manufacturing-access&#8221; model,&nbsp;laying the foundation for the future international launch of additional products.&nbsp;BioDlink focuses on ensuring international manufacturing and supply chain robustness, while Kexing BioPharm leverages its global channels to drive localized market access.<\/p>\n<p>BioDlink and Kexing BioPharm are committed to deepening their global collaboration to fulfill a shared mission of advancing global healthcare. BioDlink remains&nbsp;aligned with&nbsp;its&nbsp;&#8220;Quality First, Innovation Driven, Success Together&#8221; service philosophy to focus on emerging markets such as <span class=\"xn-location\">South America<\/span>, <span class=\"xn-location\">South Asia<\/span>, <span class=\"xn-location\">Southeast Asia<\/span> and <span class=\"xn-location\">Africa<\/span>, benefiting an even broader global patient population in the future.<\/p>\n<p><b><u>Reference:<\/u><\/b><\/p>\n<p>[1] GLOBOCAN 2022 \u2014 <span class=\"xn-location\">Colombia<\/span> factsheet (IARC)<br \/><b><u><a href=\"https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/170-colombia-fact-sheet.pdf\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/170-colombia-fact-sheet.pdf<\/a><\/u><\/b><\/p>\n<p>[2] Bevacizumab injection achieved global sales of <span class=\"xn-money\">USD 8.5 billion<\/span> in 2023.<br \/><b><u><a href=\"https:\/\/dataintelo.com\/report\/global-bevacizumab-injection-market\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/dataintelo.com\/report\/global-bevacizumab-injection-market<\/a><\/u><\/b><\/p>\n<p>[3] Top three most populous countries in <span class=\"xn-location\">South America<\/span>.<br \/><b><u><a href=\"https:\/\/en.wikipedia.org\/wiki\/List_of_South_American_countries_by_population\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/en.wikipedia.org\/wiki\/List_of_South_American_countries_by_population<\/a><\/u><\/b><\/p>\n<p><b>About BioDlink Biopharm Co., Ltd.<\/b><\/p>\n<p>BioDlink (1875.HK) is a leading global CDMO specializing in biologics and bioconjugates (ADCs\/XDCs). Headquartered in Suzhou with centers in <span class=\"xn-location\">Shanghai<\/span> and <span class=\"xn-location\">Beijing<\/span>, the company provides fully integrated, end-to-end services spanning early R&amp;D through commercial manufacturing.<\/p>\n<p>With its one-base integrated platform and proprietary technologies\u2014such as BDKcell<sup>\u00ae <\/sup>for rapid cell line development and GL-DisacLink<sup>\u00ae<\/sup> for site-specific conjugation\u2014BioDlink helps partners accelerate development, improve efficiency, and reduce costs.<\/p>\n<p>The company operates four commercial manufacturing lines with large-scale sterile fill-finish capabilities, backed by a global GMP-aligned quality system that has earned PMDA accreditation in <span class=\"xn-location\">Japan<\/span> and supported product approvals across <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Indonesia<\/span>, <span class=\"xn-location\">Nigeria<\/span>, <span class=\"xn-location\">Pakistan<\/span>, and <span class=\"xn-location\">Colombia<\/span>.<\/p>\n<p>Guided by the philosophy of &#8220;Quality First, Innovation Driven, Success Together,&#8221; BioDlink is committed to advancing global access to next-generation biologics and building trusted partnerships worldwide. For more information, please visit: <a href=\"https:\/\/www.biodlink.com\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.biodlink.com\/<\/a><\/p>\n<p><b>About Kexing Biopharm Co., Ltd.<\/b><\/p>\n<p>Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the integration of R&amp;D, production and sales of recombinant protein drugs and microecological preparations. It focuses on antiviral, tumor and immune, blood, digestion, degenerative diseases and other therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of &#8220;innovation+internationalization&#8221;, At the same time, it explores the extensive application of biotechnology in the field of general health, actively cultivates and incubates new industries, the world&#8217;s leading industrial platforms such as animal vaccines and synthetic organisms have been distributed, and is committed to becoming a leader in high-quality biopharmaceutics and serving global patients.<\/p>\n<p><b>Contact information:<br \/><\/b><a href=\"mailto:pr@biodlink.com\" target=\"_blank\" rel=\"nofollow noopener\">pr@biodlink.com<\/a><\/p>\n<\/p><\/div>\n<p>Source: BioDlink Biopharm Co., Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia[1]. This inaugural shipment\u2014dispatched around two months after Colombia&#8217;s marketing approval\u2014demonstrates the company&#8217;s efficiency, while validating its antibody commercialization platform, as well as robust production quality and supply chain management systems. SUZHOU, China, [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-41139","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioDlink Completes First International Shipment of Bevacizumab to Colombia - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=41139\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioDlink Completes First International Shipment of Bevacizumab to Colombia - My Blog\" \/>\n<meta property=\"og:description\" content=\"Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia[1]. This inaugural shipment\u2014dispatched around two months after Colombia&#8217;s marketing approval\u2014demonstrates the company&#8217;s efficiency, while validating its antibody commercialization platform, as well as robust production quality and supply chain management systems. SUZHOU, China, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=41139\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T12:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"BioDlink Completes First International Shipment of Bevacizumab to Colombia\",\"datePublished\":\"2025-10-27T12:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139\"},\"wordCount\":803,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2682341\\\/BioDlink_EN_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139\",\"name\":\"BioDlink Completes First International Shipment of Bevacizumab to Colombia - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2682341\\\/BioDlink_EN_Logo.jpg?p=medium600\",\"datePublished\":\"2025-10-27T12:30:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2682341\\\/BioDlink_EN_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2682341\\\/BioDlink_EN_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=41139#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioDlink Completes First International Shipment of Bevacizumab to Colombia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioDlink Completes First International Shipment of Bevacizumab to Colombia - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=41139","og_locale":"en_US","og_type":"article","og_title":"BioDlink Completes First International Shipment of Bevacizumab to Colombia - My Blog","og_description":"Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia[1]. This inaugural shipment\u2014dispatched around two months after Colombia&#8217;s marketing approval\u2014demonstrates the company&#8217;s efficiency, while validating its antibody commercialization platform, as well as robust production quality and supply chain management systems. SUZHOU, China, [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=41139","og_site_name":"My Blog","article_published_time":"2025-10-27T12:30:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=41139#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=41139"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"BioDlink Completes First International Shipment of Bevacizumab to Colombia","datePublished":"2025-10-27T12:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=41139"},"wordCount":803,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=41139#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=41139","url":"https:\/\/transmediavictoria.net.au\/?p=41139","name":"BioDlink Completes First International Shipment of Bevacizumab to Colombia - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=41139#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=41139#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600","datePublished":"2025-10-27T12:30:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=41139#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=41139"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=41139#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2682341\/BioDlink_EN_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=41139#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"BioDlink Completes First International Shipment of Bevacizumab to Colombia"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/41139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41139"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/41139\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}